Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 1,694 trials

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Postpartum Anemia: IV vs. Oral Iron Treatment

We are studying whether intravenous iron is more effective than oral iron in reducing postpartum depression and improving anemia in women after cesarean delivery. This trial will help us understand the best treatment options for new mothers facing these challenges.

Postpartum Depression with Iron Deficiency Anemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPsychiatry

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyPsychiatry

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Ewing Sarcoma: Regorafenib with Chemotherapy

We are studying a new combination of regorafenib and standard chemotherapy for patients with newly diagnosed multimetastatic Ewing sarcoma. The goal is to find the best dose and evaluate its safety and effectiveness.

Metastatic Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Menière's Disease: Methylprednisolone Injection Study

We are investigating whether an injection of methylprednisolone can reduce vertigo attacks in patients with Menière's disease. This study will also assess its effects on hearing and overall quality of life.

Menière's Disease1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteOtolaryngology

Lung Cancer Treatment: MK-2870 with Pembrolizumab

We are comparing a new combination treatment for metastatic non-small cell lung cancer to standard therapy. This study aims to see if the combination improves survival and quality of life for patients with high PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

Type 2 Diabetes: BCAA Oxidation Study

We are investigating whether boosting branched-chain amino acid oxidation can lower blood sugar levels in people with type 2 diabetes. The study also examines effects on insulin sensitivity, heart health, and cognitive function.

Type 2 Diabetes6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDiabetologyEndocrinology

E. coli Urinary Tract Infection: Pivmecillinam Treatment

We are studying whether an oral medication called pivmecillinam is as effective as standard treatments for E. coli urinary tract infections. This trial will also assess safety and other health effects.

Febrile Urinary Tract Infection>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesUrology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Polycystic Ovary Syndrome: Letrozole vs. Gonadotropins for Insemination

We are studying whether letrozole can be a better option than gonadotropins for achieving pregnancy in women with polycystic ovary syndrome. The trial will also examine miscarriage rates and treatment responses.

Insemination in Patients with Polycystic Ovary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Preventing Postoperative Pain in Children: Locoregional Analgesia Study

We are studying whether locoregional analgesia can help reduce long-term pain after orthopedic surgery in children. The trial compares pain levels and recovery outcomes between different pain management methods.

Postoperative Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Lung Cancer: Adagrasib Dosing Study

We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.

Non-small cell lung cancerEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology